ACHV Stock Risk & Deep Value Analysis
Achieve Life Sciences Inc
DVR Score
out of 10
What You Need to Know About ACHV Stock
We analyzed Achieve Life Sciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ACHV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ACHV Risk Analysis & Red Flags
What Could Go Wrong
The FDA could issue a Complete Response Letter (CRL) on June 20, 2026, with more stringent requirements than anticipated, significantly delaying or jeopardizing cytisinicline's approval. This would lead to a substantial stock price drop and further erode investor confidence.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Significant immediate share dilution (doubling of shares with potential for more via warrants).
- ⚠
Expected Complete Response Letter (CRL) from FDA, indicating potential delays or issues with initial submission.
- ⚠
Company remains pre-revenue with ongoing cash burn until commercial launch.
Upcoming Risk Events
- 📅
FDA issues a significant CRL requiring new clinical trials
- 📅
Slower-than-expected commercial uptake post-launch
- 📅
Further substantial share dilution
When to Reconsider
- 🚪
Negative FDA decision that significantly delays or rejects cytisinicline beyond the anticipated CRL and resubmission timeline.
- 🚪
Quarterly cash burn rates accelerate significantly without clear operational justification.
- 🚪
Commercial launch of cytisinicline yields significantly lower-than-expected sales in initial quarters.
Unlock ACHV Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Achieve Life Sciences presents a compelling high-risk, high-reward opportunity with cytisinicline poised for regulatory approval and commercialization in the vast nicotine dependence market. The recent substantial financing addresses critical liquidity concerns, backed by strong institutional investors and new leadership focused on execution. While significant dilution impacts per-share value, the long-term potential for market leadership and the de-risking of the financial pathway could drive substantial returns over the next 3-5 years.
Is ACHV Stock Undervalued?
Unlock the full AI analysis for ACHV
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ACHV Price Targets & Strategy
12-Month Target
$15.50
Bull Case
$47.40
Bear Case
$2.00
Valuation Basis
Based on 3x projected peak sales of $500M (discounted to approval) divided by ~103.4M diluted shares.
Entry Strategy
Dollar-cost average on dips towards $3.60-$4.00, which aligns with the private placement price and recent support levels.
Exit Strategy
Take initial profits at $12.00-$15.50 (analyst targets). Re-evaluate at $25.00+ for longer-term 10x potential. Stop-loss at $3.00 if regulatory setbacks occur.
Portfolio Allocation
7-10% for aggressive risk tolerance, given the high-risk, high-reward nature.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ACHV Financially Healthy?
Profitability
Operating Margin
-106.51%
Net Margin
-94.67%
Return on Equity
-204.14%
Revenue Growth
-89.25%
EPS
$-1.29
Balance Sheet
Current Ratio
4.39
Quick Ratio
4.01
Debt/Equity
0.69
Cash & Equivalents
$36.40M
Cash Flow
Free Cash Flow
-$17.98M
Other
Beta (Volatility)
2.35
Does ACHV Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat, primarily derived from intellectual property and regulatory approval, is durable until patent expiration or the emergence of significantly superior alternative treatments. This typically provides 10-20 years of exclusivity.
Moat Erosion Risks
- •Expiration of key patents leading to generic competition.
- •Development of new, more effective or safer treatments for nicotine dependence.
- •Regulatory changes impacting market access or pricing.
ACHV Competitive Moat Analysis
Sign up to see competitive advantages
ACHV Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, awaiting key regulatory and commercial milestones.
Institutional Sentiment
Positive, evidenced by a large private placement led by prominent life sciences funds (Frazier, TPG, venBio, Paradigm, Marshall Wace). Analyst consensus is 'Moderate Buy' with significant price targets.
Insider Activity (Form 4)
Andrew Goldberg, MD appointed CEO effective April 18, 2026, with significant equity awards (1% RSUs, 2% options, 6.5% performance RSUs of fully diluted shares), indicating strong alignment with future company performance.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
2026-05-12
Surprise Probability
Medium
Historical Earnings Pattern
No clear historical pattern available, but pre-revenue biopharma earnings typically see high volatility based on pipeline updates and financial runway.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no direct 'best-in-class' competitor detailed in the research for cytisinicline's specific profile). Other smoking cessation therapies (e.g., varenicline, bupropion) are broad competitors.
Market Share Trend
Not applicable pre-commercialization. Aiming to gain significant market share in underserved nicotine dependence.
Valuation vs Peers
Pre-revenue, making traditional valuation metrics challenging. Valued based on pipeline potential and probability of success, generally trading at a discount until commercialization.
Competitive Advantages
- •Differentiated receptor selectivity profile of cytisinicline (potential for better safety/tolerability vs. competitors).
- •First-mover potential in a specific niche of the nicotine cessation market.
- •Extensive clinical trial data and intellectual property protecting cytisinicline.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ACHV Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 12, 2026)
- •FDA Complete Response Letter (CRL) by PDUFA (June 20, 2026)
- •NDA Resubmission to FDA (Q4 2026)
Medium-Term (6-18 months)
- •Cytisinicline commercial launch (H1 2027)
- •Initiation and progress of Phase 3 e-cigarette cessation trial
- •Potential strategic commercialization partnerships
Long-Term (18+ months)
- •Establishment of market leadership in nicotine dependence treatment
- •Label expansion for cytisinicline
- •Global market expansion
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ACHV?
- ✓
Positive feedback from FDA following NDA resubmission and ultimate approval.
- ✓
Strong initial commercial uptake and sales trajectory post-launch.
- ✓
Timely and successful completion of Phase 3 e-cigarette cessation trial.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Achieve Life Sciences Inc Makes Money
Achieve Life Sciences is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, a plant-based alkaloid drug designed to help people stop smoking and using e-cigarettes. Currently, the company generates no product revenue and relies entirely on external funding to advance its drug development and prepare for commercialization. Its future business model is predicated on obtaining regulatory approval for cytisinicline, after which it plans to generate revenue by manufacturing and selling the drug directly or through partnerships to healthcare providers for prescription to patients suffering from nicotine addiction.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Achieve Life Sciences Inc (ACHV)?
As of April 17, 2026, Achieve Life Sciences Inc has a DVR Score of 7.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Achieve Life Sciences Inc?
Achieve Life Sciences Inc's market capitalization is approximately $256.1M..
What is the risk level for ACHV stock?
Our analysis rates Achieve Life Sciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Achieve Life Sciences Inc's revenue growing?
Achieve Life Sciences Inc has reported revenue growth of -89.3%. Revenue has been declining, which warrants closer examination.
Is ACHV stock profitable?
Achieve Life Sciences Inc has a profit margin of -94.7%. The company is currently unprofitable.
How often is the ACHV DVR analysis updated?
Our AI-powered analysis of Achieve Life Sciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 17, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ACHV (Achieve Life Sciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.